Literature DB >> 11975675

Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage Ib and IIa is a strong prognostic factor for long-term survival: analysis of the Radiumhemmet data 1989-1991.

C Beskow1, A-K Agren-Cronqvist, F Granath, B Frankendal, R Lewensohn.   

Abstract

The purpose of this study was to evaluate the treatment results of preoperative brachytherapy and the prognostic value of pathologic complete remission after preoperative intracavitary irradiation in patients with stage Ib and IIa cervical carcinoma in relation to recurrence rate and survival. The clinical records of 185 patients with stage Ib (129 patients) and IIa (56 patients) cervical carcinoma, consecutively admitted to Radiumhemmet from January 1989 to December 1991 were reviewed. The median follow-up time was 71 months. In 121 patients the treatment consisted of uterovaginal intracavitary irradiation, according to the Stockholm technique, followed by surgery. Tumor remission assessed in the surgical specimen was classified as pathologic complete remission (pCR) if no microscopic tumor was found or incomplete pathologic remission (non-pCR) if microscopic residual tumor was found. Postoperative external beam radiation was added to cases with metastases in pelvic nodes or residual tumor in the resection margins. The disease-specific 5-year survival was 87% and 75% for stage Ib and IIa, respectively, for the patient population treated with preoperative intracavitary radiotherapy and surgery. After intracavitary radiation, 79% of the patients obtained pCR of the primary tumor. Five-year survival in those with pCR was 95%, compared with 46% in those with non-pCR (P < 0.0001). Patients with pCR and no lymph node metastases had a 98% 5-year survival as compared to a 5-year survival of 64% in patients with non-pCR and node negativity (P < 0.0001). Locoregional relapses were diagnosed in 2% of the patients with pCR compared to 54% in patients with non-pCR (P < 0.0001). Multivariate analysis revealed non-pCR (RR = 6.42) and node positivity (RR = 4.59) as nonfavorable factors for survival, while tumor size was not found to be of independent significance for survival. Pathologic complete remission after intracavitary irradiation is a strong favorable prognostic factor in node-negative patients. The combination of preoperative intracavitary radiotherapy and surgery results in a high cure rate and aids in identifying patients at risk for relapse who might be subject to adjuvant therapy.

Entities:  

Mesh:

Year:  2002        PMID: 11975675     DOI: 10.1046/j.1525-1438.2002.01089.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  9 in total

1.  Pathologic complete remission after preoperative high-dose-rate brachytherapy in patients with operable cervical cancer: preliminary results of a prospective randomized multicenter study.

Authors:  Julia Vízkeleti; Ildikó Vereczkey; Georgina Fröhlich; Szilvia Varga; Katalin Horváth; Tamás Pulay; Imre Pete; Csaba Nemeskéri; Árpád Mayer; Norbert Sipos; Miklós Kásler; Csaba Polgár
Journal:  Pathol Oncol Res       Date:  2014-07-11       Impact factor: 3.201

2.  Preoperative external beam radiotherapy and reduced dose brachytherapy for carcinoma of the cervix: survival and pathological response.

Authors:  Alexandre A Jacinto; Marcus S Castilho; Paulo E R S Novaes; Pablo R Novick; Gustavo A Viani; João V Salvajoli; Robson Ferrigno; Antonio Cássio A Pellizzon; Stella S S Lima; Maria A C Maia; Ricardo C Fogaroli
Journal:  Radiat Oncol       Date:  2007-02-22       Impact factor: 3.481

3.  Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB-IIA of cervical cancer.

Authors:  C Beskow; L Kanter; A Holgersson; B Nilsson; B Frankendal; E Avall-Lundqvist; R Lewensohn
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

4.  Expression of CXCL10 is associated with response to radiotherapy and overall survival in squamous cell carcinoma of the tongue.

Authors:  Matilda Rentoft; Philip John Coates; Lotta Loljung; Torben Wilms; Göran Laurell; Karin Nylander
Journal:  Tumour Biol       Date:  2014-01-07

5.  Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis.

Authors:  Philip Junker; Julian Puppe; Fabinshy Thangarajah; Christian Domröse; Angela Cepic; Bernd Morgenstern; Dominik Ratiu; Martin Hellmich; Peter Mallmann; Marina Wirtz
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-08-20       Impact factor: 2.915

6.  Impact of Preoperative vs Postoperative Radiotherapy on Overall Survival of Locally Advanced Breast Cancer Patients.

Authors:  Yujiao Deng; Hongtao Li; Yi Zheng; Zhen Zhai; Meng Wang; Shuai Lin; Yizhen Li; Bajin Wei; Peng Xu; Ying Wu; Xinyue Deng; Si Yang; Jun Lyu; Jingjing Hu; Huaying Dong; Zhijun Dai
Journal:  Front Oncol       Date:  2021-11-23       Impact factor: 6.244

7.  Pre-operative high-dose-rate brachytherapy in early-stage cervical cancer: long-term single-center results.

Authors:  Sylwia Kellas-Ślęczka; Piotr Wojcieszek; Marta Szlag; Magdalena Stankiewicz; Agnieszka Cholewka; Maciej Ślęczka; Agnieszka Badora-Rybicka; Piotr Lelek; Agnieszka Pruefer; Tomasz Krzysztofiak; Zofia Kołosza; Marek Fijałkowski
Journal:  J Contemp Brachytherapy       Date:  2022-01-19

8.  Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86.

Authors:  C Beskow; J Skikuniene; A Holgersson; B Nilsson; R Lewensohn; L Kanter; K Viktorsson
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

9.  Biological effective dose evaluation and assessment of rectal and bladder complications for cervical cancer treated with radiotherapy and surgery.

Authors:  Catharina Beskow; Anna-Karin Agren-Cronqvist; Rolf Lewensohn; Iuliana Toma-Dasu
Journal:  J Contemp Brachytherapy       Date:  2012-12-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.